Oculis Holding AG

NasdaqGM OCS

Oculis Holding AG Net Income Margin for the year ending December 31, 2023: -10,056.85%

Oculis Holding AG Net Income Margin is -10,056.85% for the year ending December 31, 2023, a -137.01% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Oculis Holding AG Net Income Margin for the year ending December 31, 2022 was -4,243.20%, a -119.57% change year over year.
  • Oculis Holding AG Net Income Margin for the year ending December 31, 2021 was -1,932.50%, a -29.02% change year over year.
  • Oculis Holding AG Net Income Margin for the year ending December 31, 2020 was -1,497.78%.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
NasdaqGM: OCS

Oculis Holding AG

CEO Dr. Riad Sherif M.B.A., M.D.
IPO Date May 18, 2021
Location Switzerland
Headquarters Bahnhofstrasse 7
Employees 36
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

StockViz Staff

January 15, 2025

Any question? Send us an email